Market Intelligence, Epigenetic Progress, and High-Purity Reagents for Oncology & Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for H4C14 drug discovery and epigenetic screening. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | H4C14 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View H4C14 Products |
| Gene Delivery | H4C14 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View H4C14 Products |
| Benchmark Ab | Anti-H4C14 Antibody Recombinant positive control for ChIP/WB. |
View H4C14 Products |
| Validator | H4C14 siRNA Set For knockdown verification. |
View H4C14 Products |
| Related Target A | HDAC1 Critical epigenetic eraser modifying Histone H4. |
View HDAC1 Products |
| Related Target B | EZH2 Methyltransferase interacting with chromatin networks. |
View EZH2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Substrate Purity for Enzymatic Screening | High Purity (>95%) Recombinant Protein, strictly Endotoxin Controlled. |
| Isoform & Homolog Specificity | Sequence Verified against specific H4 cluster genes. |
| Lack of Reliable Controls | Sequence-verified Antibodies included for robust assay baselines. |
| Target Validation False Positives | Validated siRNA included for specificity checks. |
Live H4C14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The role of H4C14 (Histone H4) is foundational in epigenetic drug discovery. While Histone H4 itself is a structural chromatin component rather than a direct traditional drug target, the "readers, writers, and erasers" (such as HDACs, HATs, and HMTs) that modify H4 are prime therapeutic targets. The global pipeline is shifting toward highly selective small molecules and targeted protein degraders (PROTACs) addressing aberrant histone modifications in oncology and autoimmune conditions. Next-generation therapies require rigorous substrate specificity assays to map precise epigenetic interventions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (HDAC/HMT Inhibitors) | Novartis, Merck, Celgene | Hematological Malignancies, Solid Tumors | Enzymatic Assay Substrates (Need high-purity Sequence Verified proteins) |
| PROTACs / Degraders | Arvinas, Kymera | Refractory Cancers | Ternary Complex Validation (Need native-conformation proteins) |
| Autoantibody Diagnostics | Diagnostic Labs | Systemic Lupus Erythematosus (SLE) | Epitope Screening (Need accurate, pure antigens) |